{"title": "New drug development", "author": "At En Dr Patnam Mahender Reddy Institute", "url": "https://www.slideshare.net/nasertadvi/new-drug-development-180302657", "hostname": "slideshare.net", "description": "New drug development - Descargar como PDF o ver en l\u00ednea de forma gratuita", "sitename": "SlideShare", "date": "2019-10-09", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "2. Stages in new drug development\n\u2022 Drug discovery phase\n\u2013 Synthesis and isolation of compound\n\u2013 New chemical entity (NCE)\n\u2013 Takes 1-2 years\n\u2022 Preclinical studies\n\u2013 2-4 years\n\u2022 Investigational New Drug Application (IND)\n\u2013 Submission & review by FDA\n\u2013 3-6 months\n3. IND\nClinical Trials\n\u2022Phase 1\n\u2022Phase 2\n\u2022Phase 3\n3 To 10 years\nPre clinical studies continued\nPlus\n\u2022Long term animal toxicity\n\u2022Product formulation\n\u2022Manufacturing & controls\n\u2022Package & label designs\nNew Drug Application (NDA)\n\u2022Review & grant of marketing permission\n\u20220.5 to 2 years\nPost marketing surveillance (Phase -4)\nStages in new drug development\n5. Approaches to drug discovery\n\u2022 Random screening\n\u2013 Natural sources\n\u2013 Chemical Synthesis\n\u2022 Serendipity\n\u2022 Rational drug designing\n\u2013 Compound centered approach\n\u2013 Target centered approach\n\u2022 Designing a prodrug or active metabolite as a\ndrug\n6. Random screening\n\u2022 Natural Products\n\u2013 Morphine, digitalis, artemisinin, quinidine,\natropine\n\u2022 Synthetic products\n\u2013 Randomly synthesized compounds tested for\npharmacological activity\n\u2022 Barbiturates, chlorpromazine synthesized by this\napproach\n8. 1st Antibacterial Drug\nActive Metabolite of Prontosil\nFirst Oral Hypoglycemic Drug First Carbonic Anhydrase Inhibitor\nMajor Improvement in Diuretics\nNovel Hypotensive Drug First Loop Diuretics\nOther\nSulfonamides\nOther Carbonic\nAnhydrase Inhibitors\nOther Thiazide\nDiuretics\nOther Loop\nDiuretics\nOther\nSulfonylureas\nProntosil (1932)\nSulfanilamide (1935)\nCarbutamide (1955) Acetazolamide (1949)\nChlorothiazide (1957)\nDiazoxide (1961) Furosemide(1962)\n9. Drug Discovery by Serendipity\n\u2022 Happy observation by chance\n\u2022 New use of old drugs or its side effects find\nnew therapeutic application\n\u2013 Penicillin\n\u2013 Methotrexate in psoriaris\n\u2013 Sildenafil now used in impotence\n\u2013 Lignocaine as antiarrhythmic\n10. Rational drug designing\n\u2022 Compound centered approach\n\u2013 Beta blockers developed by modifying structure of\nPropranolol\n\u2013 Molecular modification/ manipulation\n\u2022 Receptor based approach ( target oriented)\n\u2013 Depends on sound knowledge & identification of\nspecific target for drug action\n11. Target oriented approach\n\u2022 Receptors\n\u2013 GPCR, Receptors with intrinsic ion channels,\nenzyme linked receptors\n\u2022 Ion channels\n\u2013 Na+, K+, Ca++ and Cl\u2013\n\u2022 Transporters\n\u2013 Na+/K+ ATPase, H+/K+ ATPase, Na+-K+-2Cl\u2013\n\u2022 Enzymes\n12. Designing of prodrug or active metabolite\nas a drug\n\u2022 Paracetamol active metabolite of phenacetin\n\u2022 N acetyl procainamide active metabolite of\nprocainamide\n\u2022 Bacampicillin prodrug of ampicillin\n\u2022 Levodopa prodrug of dopamine\n14. Pre-clinical Studies\n\u2022 Screening Tests\n\u2022 Tests on isolated organs\n\u2022 Tests on bacterial cultures\n\u2022 Tests on animal models of human diseases\n\u2013 Diabetic rats / dogs by diazoxide\n\u2013 Kindled animals for anti-epileptic drugs\n\u2022 General observational tests on intact animals\n17. Good Laboratory Practice (GLP)\n\u2022 Embodies a set of principles that provides a\nframework within which laboratory studies\nare planned, performed, monitored, recorded,\nreported and archived.\n18. Before Clinical Studies\n\u2022 Drug is formulated into a suitable dosage form\n\u2022 The clinical trials are done under the guideline\nof Good Clinical Practice (GCP) laid down by\nInternational Conference on Harmonization\n(ICH)\n19. Investigational New Drug (IND)\n\u2022 IND license is obtained after successful\ncompletion of pre-clinical studies from\nregulatory authorities.\n\u2022 Regulatory Authority\n\u2013 India: Drug Control General of India (DCGI)\n\u2013 USA: FDA (Food and Drug Administration)\n20. Good Clinical Practice (GCP)\n\u2022 GCP include\n\u2013 Protection of human rights as a subject in clinical trial.\n\u2013 Provides assurance of the safety and efficacy of the\nnewly developed compounds.\n\u2022 Good Clinical Practice Guidelines include\nstandards on\n\u2013 how clinical trials should be conducted,\n\u2013 define the roles and responsibilities of clinical\ntrial sponsors, clinical research investigators, and\nmonitors.\n21. Phases of Clinical Trials\n\u2022 Phase I\nEarly Clinical Pharmacology & Safety\n\u2022 Phase II\nTherapeutic exploration and dose ranging\n\u2022 Phase III\nTherapeutic confirmation and comparison\n\u2022 Phase IV\nPost-marketing Surveillance / Studies\n22. Phases of Clinical Trials\n\u2022 In Each Phase\n\u2013 Exposure to greater numbers of human subjects\n\u2013 Collection of increasing amounts of data on safety\nand efficacy of the drug\nI II III IV\n23. PHASE I\n(Early clinical Pharmacology and safety)\n\u2022 N = 20 \u2013 80 healthy human volunteers\n(sometimes patients)\n\u2022 Carried out by qualified clinical pharmacologists\nor trained physicians\n\u2022 Carried out in emergency settings\n\u2022 No blinding, open label\n\u2022 Approx duration 1 year\n24. PHASE I\n\u2022 Emphasis : Safety and Tolerability\n\u2022 Started with lowest estimated dose and stepwise\nincreased to effective dose.\n\u2022 Data collection on\n\u2013 Pharmacokinetics\n\u2013 Systemic pharmacodynamics\n\u2013 General adverse effects\n\u2022 Acceptable dosing level is found\n25. PHASE II\n(Therapeutic exploration and dose ranging)\n\u2022 Inclusion and exclusion criteria are fixed\n\u2022 N = 100 \u2013 500 patients\n\u2022 Carried out by trained physicians\n\u2022 Duration: 2-3 years\n\u2022 Type: Open label / Blind\n\u2022 Venue: 2 \u2013 4 centres\n\u2022 Establishment of therapeutic efficacy\n\u2022 Dose range for more definitive therapeutic trial\nidentified\n26. PHASE III\n(Therapeutic confirmation/ comparison)\n\u2022 Aim is to compare new drug to existing therapy\n\u2022 Safety and tolerability assessed on higher scale\n\u2022 Indications are finalized and guidelines for\ntherapeutic use formulated\n\u2022 Multicentric, Randomized, Placebo controlled,\nComparative, Double-blind\n\u2022 Involves several physicians\n\u2022 N = 500 to 3000 patients\n27. Registration\n\u2022 New Drug Application (NDA) along with the\nData (safety and efficacy) of Clinical Trials are\nsubmitted to relevant Regulatory Authority\n\u2013 India: DCGI (Drug Controller General of India)\n\u2022 Regulatory Authority, in convinced, gives a\n\u2018marketing permission\n\u2022 Average time for approval: 2.5 yr\n28. PHASE IV:\nPost-marketing Surveillance (PMS)\n\u2022 Practicing physicians are identified and data\ncollected on a structured proforma regarding\n\u2013 Efficacy, tolerability and Adverse effects\n\u2022 n = 4000 \u2013 5000 patients or more\n\u2022 Uncommon rare and long term adverse drug\nreactions and unsuspected drug interactions found\nout\n\u2022 Additional indications\n29. PHASE IV:\nPost-marketing Surveillance (PMS)\n\u2022 Effect on special groups\n\u2013 Elderly & Neonates\n\u2013 Pregnancy & Lactation\n\u2013 Liver &Renal impairment\n\u2022 Exploration of possibilities\n\u2013 Modified release dosage form\n\u2013 Additional route of administration\n\u2013 Fixed dose combination\n\u2022 Even drugs / formulations are withdrawn from\nthe market if found to be injurious to health\n30. Examples of drug withdrawal\n\u2022 Antihistamine: Terfenadine, Astemizole\n\u2022 Selective COX-II inhibitor: Rofecoxib and\nCelecoxib - cardiotoxicity\n\u2022 Nimesulide banned for all in Western\ncountries & for pediatric group in India\n\u2022 Aspirin liquid formation: due to possibilities\nof producing Reye\u2019s Syndrome in children", "language": null, "image": "https://cdn.slidesharecdn.com/ss_thumbnails/newdrugdevelopment-191009075742-thumbnail.jpg?width=640&height=640&fit=bounds", "pagetype": null, "links": ["https://es.slideshare.net/", "https://es.slideshare.net/nasertadvi?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview", "https://es.slideshare.net/nasertadvi?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview", "https://es.slideshare.net/nasertadvi?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview", "https://es.slideshare.net/nasertadvi?utm_campaign=profiletracking&utm_medium=sssite&utm_source=ssslideview", "https://es.slideshare.net/DrGangaprasadWaghmar/new-drug-development-67251714", "https://es.slideshare.net/AudumbarMali1/1-unit-i-new-drug-discovery-and-development", "https://es.slideshare.net/jayaprakash373/ich-and-ich-guidelines", "https://es.slideshare.net/debashishsarkar22/pre-clinical-studies", "https://es.slideshare.net/Azeemsales/preclinical-studies", "https://es.slideshare.net/nasimarshadi/drug-development-process-62544651", "https://es.slideshare.net/ckoppala/clinical-studies-250142149", "https://es.slideshare.net/SuvartaMaru1/schedules-of-drugs", "https://es.slideshare.net/RahulGawande13/drug-regulatory-authority", "https://es.slideshare.net/AudumbarMali1/2-unit-ii-chapter2-regulatory-authorities-and-agencies", "https://es.slideshare.net/AakankshaPriya1/stages-of-drug-development-186846633", "https://es.slideshare.net/sagarsavale1/investigational-new-drug-application-inda", "https://es.slideshare.net/ckoppala/clinical-studies-250142149", "https://es.slideshare.net/SuvartaMaru1/schedules-of-drugs", "https://es.slideshare.net/RahulGawande13/drug-regulatory-authority", "https://es.slideshare.net/AudumbarMali1/2-unit-ii-chapter2-regulatory-authorities-and-agencies", "https://es.slideshare.net/AakankshaPriya1/stages-of-drug-development-186846633", "https://es.slideshare.net/sagarsavale1/investigational-new-drug-application-inda", "https://es.slideshare.net/somucology/med-dra-basics", "https://es.slideshare.net/parishukla15/regulatory-affairs-in-pharmaceutical-industry", "https://es.slideshare.net/rahul_pharma/drug-discovery-and-development-10698574", "https://es.slideshare.net/AsmaAshraf7/pharmacoeconomics-80506968", "https://es.slideshare.net/tulasiraman/pharmacovigilance-23894909", "https://es.slideshare.net/BiNduXtrEiy/investigational-new-drug-application", "https://es.slideshare.net/Anilpawar53/central-drug-standard-control-organisation-cdsco-209674868", "https://es.slideshare.net/DipakBhingardeve/regulatory-affairs-238230245", "https://es.slideshare.net/rajud521/drug-development-and-regulation", "https://es.slideshare.net/bharathpharmacist/anda-39685626", "https://es.slideshare.net/bdvfgbdhg/central-drug-standard-control-organisation", "https://es.slideshare.net/aiswarya95thomas/various-approaches-to-drug-discovery", "https://es.slideshare.net/boreddysunilkumarreddy/drug-development-and-clinical-trial-phases", "https://es.slideshare.net/VKEkbote/new-drug-application", "https://es.slideshare.net/bishalaran/clinical-trials-by-khadga", "https://es.slideshare.net/VibhaManu/clinical-trials-64582910", "https://es.slideshare.net/roohna/schedule-y-by-drroohna", "https://es.slideshare.net/neel_sh/drug-discovery-15390294", "https://es.slideshare.net/rahulbhati5095/clinical-trials-and-new-drug-development", "https://es.slideshare.net/RavishYadav8/phases-of-clinical-trials-238300234", "https://es.slideshare.net/bishalaran/clinical-trials-by-khadga", "https://es.slideshare.net/VibhaManu/clinical-trials-64582910", "https://es.slideshare.net/roohna/schedule-y-by-drroohna", "https://es.slideshare.net/neel_sh/drug-discovery-15390294", "https://es.slideshare.net/rahulbhati5095/clinical-trials-and-new-drug-development", "https://es.slideshare.net/RavishYadav8/phases-of-clinical-trials-238300234", "https://es.slideshare.net/PharmacologyVydehiVy/molecule-to-medicine", "https://es.slideshare.net/SameerKhasbage/drug-development-process-and-clinical-trial-for-ugs", "https://es.slideshare.net/ssuser660bb1/protocolspptx-254134790", "https://es.slideshare.net/jobinkv/clinical-research-a-basic-understanding", "https://es.slideshare.net/NileshSiddhawar/clinical-trials-79412411", "https://es.slideshare.net/jireankita/scope-of-pharmacology", "https://es.slideshare.net/SabeenaChoudhary/phases-of-a-clinical-trial-and-accelerated-drug", "https://es.slideshare.net/GagandeepJaiswal/a-presentation-on-different-phases-of-clinical-trials-investigational-new-drug-new-drug-application", "https://es.slideshare.net/ckoppala/clincial-trials-and-types", "https://es.slideshare.net/ssuserb1107c/evaluation-of-the-evidence-of-the-drug-development", "https://es.slideshare.net/garginanda93/introduction-to-preclinical-trials", "https://es.slideshare.net/carriemoconnor/the-investigational-new-drug-ind-and-new-drug-application-nda-process", "https://es.slideshare.net/maryaahsan7/process-of-new-drug-development-amp-approval", "https://es.slideshare.net/_tulsi_333/an-overview-of-drug-discovery-and-development-process", "https://es.slideshare.net/nasertadvi/evidence-based-medicine-and-tdm", "https://es.slideshare.net/nasertadvi/immunopharmacology-238704856", "https://es.slideshare.net/nasertadvi/drug-therapy-in-pediatric-and-geriatric-age-groups", "https://es.slideshare.net/nasertadvi/vaccines-and-antisera", "https://es.slideshare.net/nasertadvi/antimalarial-drugs-238040661", "https://es.slideshare.net/nasertadvi/drugs-for-leprosy", "https://es.slideshare.net/nasertadvi/evidence-based-medicine-and-tdm", "https://es.slideshare.net/nasertadvi/immunopharmacology-238704856", "https://es.slideshare.net/nasertadvi/drug-therapy-in-pediatric-and-geriatric-age-groups", "https://es.slideshare.net/nasertadvi/vaccines-and-antisera", "https://es.slideshare.net/nasertadvi/antimalarial-drugs-238040661", "https://es.slideshare.net/nasertadvi/drugs-for-leprosy", "https://es.slideshare.net/nasertadvi/pharmacotherapy-of-tuberculosis-237379855", "https://es.slideshare.net/nasertadvi/cephalosporins-236934211", "https://es.slideshare.net/nasertadvi/penicillins-236933956", "https://es.slideshare.net/nasertadvi/drugs-for-treatment-of-diabetes-mellitus", "https://es.slideshare.net/nasertadvi/drugs-affecting-calcium-balance-235422580", "https://es.slideshare.net/nasertadvi/parkinsonism-treatment", "https://es.slideshare.net/nasertadvi/serotonin-and-anti-serotonin-drugs", "https://es.slideshare.net/nasertadvi/introduction-to-ans", "https://es.slideshare.net/nasertadvi/alpha-blockers-206199086", "https://es.slideshare.net/nasertadvi/histamine-and-antihistaminic", "https://es.slideshare.net/nasertadvi/introduction-to-autonomic-nervous-system-199679145", "https://es.slideshare.net/nasertadvi/beta-blockers-199677174", "https://es.slideshare.net/nasertadvi/anticholinergic-drugs-199673247", "https://es.slideshare.net/nasertadvi/bioassay-199670858", "https://es.slideshare.net/PeerVoice/indolent-isnt-insignificant-raising-awareness-of-systemic-mastocytosis-and-its-symptoms", "https://es.slideshare.net/Bhaskarbhukya/theory-of-healing-abilities-of-wild-fishes-and-recovery-of-injured-gift-tilapiadocx", "https://es.slideshare.net/AhmedMshari/polypharmacy-and-rational-prescribing-in-elderly-patientspptx", "https://es.slideshare.net/LifecareCentre/lets-talk-making-india-iron-strong-dr-sharda-jain", "https://es.slideshare.net/rjoson/rojoson-pep-talk-epidermal-cysts-in-skin", "https://es.slideshare.net/IbrahimAboAlasaad/imaging-radioklogy-and-us-for-protozoal-diseasespptx", "https://es.slideshare.net/PeerVoice/indolent-isnt-insignificant-raising-awareness-of-systemic-mastocytosis-and-its-symptoms", "https://es.slideshare.net/Bhaskarbhukya/theory-of-healing-abilities-of-wild-fishes-and-recovery-of-injured-gift-tilapiadocx", "https://es.slideshare.net/AhmedMshari/polypharmacy-and-rational-prescribing-in-elderly-patientspptx", "https://es.slideshare.net/LifecareCentre/lets-talk-making-india-iron-strong-dr-sharda-jain", "https://es.slideshare.net/rjoson/rojoson-pep-talk-epidermal-cysts-in-skin", "https://es.slideshare.net/IbrahimAboAlasaad/imaging-radioklogy-and-us-for-protozoal-diseasespptx", "https://es.slideshare.net/pradeepbansal34/optimization-of-heart-failure-treatment-pptpptx", "https://es.slideshare.net/IbrahimAboAlasaad/2-chest-soft-tisue-radiological-for-helminth-infectionspptx", "https://es.slideshare.net/rjoson/rojoson-pep-talk-gout-arthritis", "https://es.slideshare.net/rjoson/rojoson-pep-talk-national-thyroid-cancer-awareness-week-2023", "https://es.slideshare.net/lkcyber/the-longevity-dividend-what-advancements-in-longevity-science-mean-for-individuals-society-the-economy-and-the-military", "https://es.slideshare.net/SuparnamoomBanerjee/optimizing-cardiac-healthpptx", "https://es.slideshare.net/RanjanaRavindran1/screw-retained-vs-cement-retained-prosthesispptx", "https://es.slideshare.net/DavidRonen3/flowzz-marketupdateteaserpdf", "https://es.slideshare.net/SujoyDasgupta1/endometriosis-and-subfertility-what-to-do", "https://es.slideshare.net/OlafKrausdeCamargo/how-participatory-action-research-par-informed-practice-and-policy-at-a-canadian-childhood-disability-research-organization-reflections-from-canchild", "https://es.slideshare.net/kanhucpatro/sep-2023-oncology-cartoons", "https://es.slideshare.net/UCTICO/science-of-flavors-in-tobacco-products-sept-2023", "https://es.slideshare.net/ExcellenceFoundation/masterclass-the-science-of-wellbeing-know-diabetes-hypertension-stroke", "https://es.slideshare.net/JoscelynHarris/professional-portfolio-pnur100pptx-260818786", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#1", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#2", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#3", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#5", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#6", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#7", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#8", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#9", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#10", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#11", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#12", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#13", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#14", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#15", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#16", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#17", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#18", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#19", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#20", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#21", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#22", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#23", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#24", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#25", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#26", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#27", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#28", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#29", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#30", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#31", "https://es.slideshare.net/about", "https://support.scribd.com/hc/es/categories/360004792932-SlideShare?userType=SlideShare", "https://support.scribd.com/hc/es/articles/210129326-General-Terms-of-Use", "https://support.scribd.com/hc/es/articles/210129366-Privacy-policy", "https://es.slideshare.net/copyright-policy", "https://es.slideshare.net/nasertadvi/new-drug-development-180302657?next_slideshow=true#", "https://support.scribd.com/hc/en-us/articles/360038016931-Privacy-Rights-Request-Form", "https://twitter.com/slideshare", "https://www.slideshare.net/rss/latest"]}